Parkinson's disease is one of the most common neurological conditions, estimated to affect around 250 people per 100 000 in the UK. 1 People with Parkinson's disease classically present with motor symptoms including bradykinesia, rigidity, rest tremor, and postural instability; however, non-motor symptoms may also be prominent, including depression, cognitive impairment, and autonomic disturbances.
This article summarises the most recent update to the National Institute for Health and Care Excellence (NICE) guideline for the diagnosis and management of Parkinson's disease in adults. 2 This NICE guideline provides an update on most aspects of managing Parkinson's disease, incorporating knowledge generated by a series of recent, large scale, independently funded, randomised trials in Parkinson's therapy, and replaces guidance published in 2006. The update reflects emerging experience in areas such as impulse control disorders that may coexist with Parkinson's disease and provides recommendations on the use of treatments that may provide some relief from the distressing symptoms of advanced Parkinson's disease. The guideline update has not changed the suggested approach to the diagnosis of Parkinson's disease, communication with people with Parkinson's disease and their carers, pharmacological neuroprotective therapy, and interventions by Parkinson's disease nurse specialists. Recommendations, full details of evidence, and the NICE pathway are available via the NICE website (www.nice.org.uk/guidance/ng71).
Recommendations
NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.
Diagnosis
Parkinson's disease remains a clinical diagnosis based on the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for Parkinson's disease 3 (see box 1).
Pharmacological management of motor symptoms
Involve the person with Parkinson's disease and family members and carers (as appropriate) in all decisions. Take account of their clinical and lifestyle circumstances, their preferences, needs and goals, and how they view the potential benefits and harms of different drug classes.
First line treatment
Oral levodopa remains the preferred first line medicine for people with troublesome motor symptoms. When starting treatment, give information about adverse events. For dopamine therapy, these adverse events may include impulse control disorders (particularly dopamine agonists), excessive sleepiness, and hallucinations and delusions (all Parkinson's disease treatments but particularly dopamine agonists). Table 1⇓ lists the benefits and harms from first line drugs, and the infographic outlines the general strategy for managing Parkinson's disease symptoms.
• 
Adjuvant treatment of motor symptoms
When a person with Parkinson's disease develops dyskinesia or motor fluctuations (including "wearing off" episodes when effects of medication start to wear off in between medication doses) adjuvant therapy may be added, on advice from a healthcare professional with specialist expertise in Parkinson's disease. 
Impulse control disorders as an adverse effect of dopaminergic therapy
People with impulse control disorders (ICDs) fail to resist the temptation to perform an act harmful to themselves or others such as compulsive gambling, hypersexuality, binge eating, and obsessive shopping. They are a recognised adverse effect of dopamine-replacement therapies, and occur in 14-24% of patients with Parkinson's disease who are taking these medications. ICD behaviours can cause distress for patients and carers, financial difficulties, and even criminal convictions. They may be difficult to recognise, particularly if patients conceal their behaviour from carers and family. ICD behaviours can develop in a person with Parkinson's disease who is taking any dopaminergic therapy, particularly dopamine agonists, at any stage in the disease. They are also associated with previous impulsive behaviours and a history of alcohol consumption or smoking.
• When starting dopamine agonist therapy, give people and their family members and carers (as appropriate) oral and written information about the following, and record that the discussion has taken place: -The increased risk of developing ICD behaviours when taking dopamine agonist therapy, and that these behaviours may be concealed by the person affected 
Management of non-motor symptoms
Rule out possible pharmacological and physical causes of any new non-motor symptoms, and think about non-pharmacological treatments (for example, speech and language therapy for saliva management) before prescribing medicines.
Non-pharmacological management
Consider referral for assessment and advice from specialist physiotherapists, occupational therapists, speech and language therapists, and dietitians early in the disease. Always offer these therapies under the following circumstances: 
Pharmacological management
Box 2 summarises the medicines recommended for persistent symptoms. Some of these recommendations represent off-label use of the medicine in question; follow GMC advice when prescribing. 4
Management of advanced Parkinson's disease
Deep brain stimulation may be considered for people with advanced Parkinson's disease, but only when symptoms are not controlled with best medical therapy (which may include intermittent apomorphine injection or continuous subcutaneous apomorphine infusion). Analysis undertaken for the guideline showed that levodopa-carbidopa intestinal gel is not cost effective in people with advanced Parkinson's disease; therefore, the guideline recommends that NHS England reviews its current specialised commissioning policy 6 in the light of this information.
• Consider referring people at any stage of Parkinson's disease to the palliative care team to give them and their family members or carers (as appropriate) the opportunity to discuss palliative care and care at the end of life. [Based on the experience and opinion of the GDG]
Implementation
The guidance recommends specialist care-including physiotherapy, occupational therapy, and cognitive behavioural therapy specifically for Parkinson's disease-after reviewing evidence demonstrating its effectiveness and considering its costs. However, the Guideline Development Group recognised that access to some or all of these services is limited in some areas. Similarly, provision of Parkinson's disease specialist nurses remains patchy, although NICE has recommended the services they provide for over a decade. The Department of Health has asked NICE to prepare quality standards for Parkinson's disease; we hope that these will provide additional impetus for access to these effective therapies. *Off-label use.
Guidelines into practice
• Do you provide oral and written information about adverse events including impulse control disorders when starting dopaminergic medicines?
• Do you refer people with Parkinson's disease for physiotherapy, occupational therapy, and speech and language therapy when they develop relevant symptoms?
• Have you discussed palliative care preferences with your Parkinson's disease patients?
Methods
The Guideline Development Group (GDG) comprised three consultant neurologists, two general practitioners, two consultant physicians, a Parkinson's disease specialist nurse, a Parkinson's disease nurse consultant, a specialist physiotherapist, a consultant neuropsychiatrist, a neurology specialist pharmacist, and two patient/carer members. Co-opted experts included two occupational therapists, a neurosurgeon, a speech and language therapist, and a specialist dietitian.
The guideline was developed using standard NICE guideline methodology (2012) (www.nice.org.uk/process/pmg6/chapter/introduction). The GDG developed clinical questions, collected and appraised clinical evidence, and evaluated the cost effectiveness of proposed interventions and management strategies through literature review and economic considerations where possible. Quality ratings of the evidence were based on GRADE methodology (www.gradeworkinggroup.org). These relate to the quality of the available evidence for assessed outcomes rather than the quality of the clinical study. Where standard methods could not be applied, a customised quality assessment was done. Stakeholder consultation was undertaken at both the scoping and development stages.
How patients were involved in the creation of this article
No patients were involved in the creation of this summary. However, committee members involved in this guideline included lay members who contributed to the formulation of the recommendations summarised here. The views of multiple patient organisations were sought for both the original scope of the guideline and its draft recommendations.
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Occupational therapy
Offer PD-specific occupational therapy for people who are having:
Speech and language
Offer speech and language therapy for people with PD who are experiencing:
Specialist nursing
People with PD should have regular access to the services provided by a PD nurse specialist
Palliative care
Consider referring people at any stage of PD to the palliative care team to discuss their priorities for care at the end of life 
